(Colorectal Cancer) Is Panitumumab Plus FOLFOXIRI Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Panitumumab Plus FOLFOXIRI in RAS Wild-Type Metastatic Colorectal Cancer
- December 30, 2019
- Reading time: 2 minutes
Updated: February 13, 2020
On October 10, 2019, Dominik P. Modest published in the Journal of Clinical Oncology the VOLFI/AIO KRK0109 Phase 2 trial results: "Efficacy and safety of anti-EGFR antibody panitumumab (Vectibix) plus FOLFOXIRI chemotherapy in treatment-naive RAS wild-type metastatic colorectal cancer patients."
Trial Design
The VOLFI/AIO KRK0109 Phase 2 trial was an open-label study in 96 treatment-naive patients with RAS wild-type metastatic colorectal cancer, randomized 2:1 to:
- Panitumumab + FOLFOXIRI group (N=63)
- FOLFOXIRI group (N=33)
Primary endpoint: ORR. Secondary endpoints: secondary resection rate, OS, and PFS.
Efficacy Results
ORR (primary endpoint):
- Panitumumab + FOLFOXIRI group: 87.3% / FOLFOXIRI group: 60.6%
- The panitumumab + FOLFOXIRI group exceeded the trial's predefined threshold (75%) and was significantly higher than FOLFOXIRI alone
Secondary resection rate:
- Panitumumab + FOLFOXIRI group: 33.3% / FOLFOXIRI group: 12.1% — improved in the combination group
Both groups had similar PFS. OS was also improved in the panitumumab + FOLFOXIRI group.
Conclusions
Based on the VOLFI/AIO KRK0109 trial results, Dominik P. Modest concluded that anti-EGFR antibody panitumumab plus FOLFOXIRI improved both objective response rate and resection rate compared to FOLFOXIRI alone in treatment-naive RAS wild-type metastatic colorectal cancer patients, making it a promising new treatment option for this population.
Source: FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Oct 14.
Tags: #ColorectalCancer #Panitumumab #Vectibix
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4